ImmunityBio Stock Soars After EU Grants Conditional Approval for Anktiva
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy IBRX?
Source: NASDAQ.COM
- Significant Stock Surge: ImmunityBio's stock closed at $8.54 on Wednesday, reflecting a 41.86% increase, primarily driven by the European Commission's conditional marketing authorization for Anktiva to treat bladder cancer, which significantly boosted market confidence.
- Surge in Trading Volume: The trading volume reached 78.5 million shares, approximately 178% above the three-month average of 28.2 million shares, indicating strong investor interest and engagement regarding the company's future prospects.
- Market Expansion Opportunities: The EU authorization allows ImmunityBio to access over 30 new countries, likely accelerating sales growth for its flagship immunotherapy and further solidifying its market position in the biotechnology sector.
- Investment Risk Advisory: Although Anktiva shows promising treatment potential, ImmunityBio's stock remains volatile, and investors should exercise caution, particularly given the company's dependence on positive news regarding its main immunotherapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.140
Low
5.00
Averages
7.33
High
9.00
Current: 7.140
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting potential legal repercussions from improper marketing practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that promotional materials falsely claimed Anktiva could cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to come forward, indicating that the company's legal risks could adversely affect future financing and market trust.
- Public Health Impact: The FDA emphasized that ImmunityBio's misleading claims not only jeopardize investor interests but also pose serious public health risks by creating false expectations about Anktiva's treatment capabilities, potentially misleading patients regarding their treatment options.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Computer Lawsuit: Super Micro Computer (NASDAQ:SMCI) faces a class action lawsuit for failing to disclose that sales to Chinese companies violated U.S. export control laws, with investor losses exceeding $50,000 and a lead plaintiff deadline of May 26, 2026, potentially damaging the company's reputation and stock price.
- ImmunityBio Issues: ImmunityBio (NASDAQ:IBRX) is being sued for overstating Anktiva's capabilities, with investor losses during the class period potentially affecting future financing, and the lead plaintiff deadline is also May 26, 2026.
- Pinterest Revenue Decline: Pinterest (NYSE:PINS) faces a class action lawsuit for not disclosing risks of declining advertising revenues, with investor losses before February 12, 2026, possibly leading to company restructuring, and the lead plaintiff deadline is May 29, 2026.
- New Era Energy Fraud Allegations: New Era Energy (NASDAQ:NUAI) is being sued for overstating progress on its Texas data center project and involvement in fraudulent schemes, with investor losses potentially impacting financial transparency, and the lead plaintiff deadline is June 1, 2026.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Investor Rights Protection: Affected investors are encouraged to contact the Schall Law Firm before May 26, 2026, to participate in the lawsuit and seek compensation for their losses, demonstrating a commitment to safeguarding investor rights.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, underscoring the importance of participating in the lawsuit to protect their interests.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio (IBRX) on behalf of investors who purchased securities between January 19 and March 24, 2026, highlighting serious concerns over the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, leading to investor misconceptions about the company's prospects and impacting their investment decisions.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price to $7.42 per share, reflecting a decline in market confidence in the company.
- Investor Action Recommendation: Investors are advised to apply for lead plaintiff status by May 26, 2026, to represent all affected investors, indicating the urgency and necessity of seeking compensation through legal action.
See More
ImmunityBio Securities Fraud Class Action Reminder
- Lawsuit Background: A class action lawsuit has been filed on behalf of investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, alleging that Executive Chairman Patrick Soon-Shiong materially overstated the capabilities of Anktivas, an FDA-approved immunotherapy, leading to investor losses.
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, stating that a TV ad and podcast were deemed “false or misleading,” and referenced previous Untitled Letters sent to its subsidiary Altor BioScience, indicating the company failed to rectify its promotional practices.
- Stock Price Impact: Following the FDA warning, ImmunityBio's stock price plummeted by 21.2%, from $9.40 per share on March 23, 2026, to $7.41, resulting in a loss of $1.99 per share, reflecting a pessimistic market outlook on the company's future.
- Investor Action Required: Investors must apply for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, as the lead plaintiff will significantly influence litigation strategy and settlement, ensuring their rights are protected.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that may lead to further investor losses.
- Efficacy Claims Controversy: Soon-Shiong claimed in a podcast that Anktiva could treat all cancers, while the FDA stated that these promotional materials mislead the public and fail to provide complete information regarding Anktiva's FDA-approved indications, posing potential public health risks.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and encouraging witnesses to assist in the investigation, demonstrating a strong commitment to investor rights and a demand for greater corporate transparency.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting potential legal repercussions from improper marketing practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that promotional materials falsely claimed Anktiva could cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to come forward, indicating that the company's legal risks could adversely affect future financing and market trust.
- Public Health Impact: The FDA emphasized that ImmunityBio's misleading claims not only jeopardize investor interests but also pose serious public health risks by creating false expectations about Anktiva's treatment capabilities, potentially misleading patients regarding their treatment options.
See More
Multiple Companies Face Class Action Lawsuits
- Super Micro Computer Lawsuit: Super Micro Computer (NASDAQ:SMCI) faces a class action lawsuit for failing to disclose that sales to Chinese companies violated U.S. export control laws, with investor losses exceeding $50,000 and a lead plaintiff deadline of May 26, 2026, potentially damaging the company's reputation and stock price.
- ImmunityBio Issues: ImmunityBio (NASDAQ:IBRX) is being sued for overstating Anktiva's capabilities, with investor losses during the class period potentially affecting future financing, and the lead plaintiff deadline is also May 26, 2026.
- Pinterest Revenue Decline: Pinterest (NYSE:PINS) faces a class action lawsuit for not disclosing risks of declining advertising revenues, with investor losses before February 12, 2026, possibly leading to company restructuring, and the lead plaintiff deadline is May 29, 2026.
- New Era Energy Fraud Allegations: New Era Energy (NASDAQ:NUAI) is being sued for overstating progress on its Texas data center project and involvement in fraudulent schemes, with investor losses potentially impacting financial transparency, and the lead plaintiff deadline is June 1, 2026.
See More
ImmunityBio Faces Class Action Lawsuit Reminder
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against ImmunityBio for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between January 19 and March 24, 2026.
- False Statement Allegations: The complaint alleges that ImmunityBio made false and misleading statements regarding the capabilities of its Anktiva drug, resulting in investor losses when the truth emerged, highlighting significant deficiencies in the company's disclosure practices.
- Investor Rights Protection: Affected investors are encouraged to contact the Schall Law Firm before May 26, 2026, to participate in the lawsuit and seek compensation for their losses, demonstrating a commitment to safeguarding investor rights.
- Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs, underscoring the importance of participating in the lawsuit to protect their interests.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio (IBRX) on behalf of investors who purchased securities between January 19 and March 24, 2026, highlighting serious concerns over the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, leading to investor misconceptions about the company's prospects and impacting their investment decisions.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price to $7.42 per share, reflecting a decline in market confidence in the company.
- Investor Action Recommendation: Investors are advised to apply for lead plaintiff status by May 26, 2026, to represent all affected investors, indicating the urgency and necessity of seeking compensation through legal action.
See More
ImmunityBio Securities Fraud Class Action Reminder
- Lawsuit Background: A class action lawsuit has been filed on behalf of investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, alleging that Executive Chairman Patrick Soon-Shiong materially overstated the capabilities of Anktivas, an FDA-approved immunotherapy, leading to investor losses.
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, stating that a TV ad and podcast were deemed “false or misleading,” and referenced previous Untitled Letters sent to its subsidiary Altor BioScience, indicating the company failed to rectify its promotional practices.
- Stock Price Impact: Following the FDA warning, ImmunityBio's stock price plummeted by 21.2%, from $9.40 per share on March 23, 2026, to $7.41, resulting in a loss of $1.99 per share, reflecting a pessimistic market outlook on the company's future.
- Investor Action Required: Investors must apply for lead plaintiff status by May 26, 2026, to represent other investors in the lawsuit, as the lead plaintiff will significantly influence litigation strategy and settlement, ensuring their rights are protected.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that may lead to further investor losses.
- Efficacy Claims Controversy: Soon-Shiong claimed in a podcast that Anktiva could treat all cancers, while the FDA stated that these promotional materials mislead the public and fail to provide complete information regarding Anktiva's FDA-approved indications, posing potential public health risks.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and encouraging witnesses to assist in the investigation, demonstrating a strong commitment to investor rights and a demand for greater corporate transparency.
See More
